26 Oct, 2022 NfL Biomarker Findings for hATTR Amyloidosis with Polyneuropathy Presented at ANA 2022
New 18-month findings evaluating Neurofilament light chain (NfL) as a potential biomarker of treatment response in patients with hATTR amyloidosis with polyneuropathy were presented at the 147th annual meeting of the American Neurological Association (ANA).